Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial

• Published in: BMC cancer 2022-10, Vol.22 (1), p.1-1079, Article 1079
• Main Authors: Nabi-Meybodi, Mohsen, Sahebnasagh, Adeleh, Hakimi, Zahra, Shabani, Masoud, Shakeri, Ali Asghar, Saghafi, Fatemeh
• Format: Article
• Language: English
• Subjects: Adrenergic receptors; Antioxidants; Breast cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical trial; Clinical trials; Complications and side effects; Cytokines; Dermatitis; Free radicals; Health aspects; Inflammation; Laboratories; Pathogenesis; Patients; Placebos; Population studies; Prevention; Quality of life; Radiation therapy; Radiodermatitis; Radiotherapy; Risk factors; Skin; Steroids; Terminology; Testing; Timolol; Timolol maleate; Women; Wound healing
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-10064-x

Introduction Radiation therapy is one of the standard methods in the treatment of breast cancer. Radiotherapy-induced dermatitis (RID) is a common complication of radiotherapy (RT) resulting in less tolerance in RT and even discontinuation of treatment. Timolol is a [beta]-adrenergic receptor antagonist that presents the best wound healing effects on both chronic and incurable wound healing. Topical forms of timolol could be effective in the prevention of RID due to the role of [beta]-adrenergic receptors in skin cells and keratinocyte migration, as well as the anti-inflammatory effect of timolol. However, no placebo-controlled randomized trial is available to confirm its role. The current trial aimed to evaluate the efficacy of topical timolol 0.5% (w/w) on the RID severity and patients' quality of life (QOL). Method Patients aged older than 18 years with positive histology confirmed the diagnosis of invasive and localized breast cancer were included. Patients were randomized based on the random number table to receive each of the interventions of timolol 0.5% (w/w) or placebo topical gels from the first day of initiation of RT and for 6 weeks, a thin layer of gel twice daily. Patients were asked to use a thin layer of gel for at least two hours before and after radiation therapy. Primary outcomes were acute radiation dermatitis (ARD) grade using Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer (RTOG/EORTC) scale and severity of desquamation based on Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Secondary outcomes were QOL based on Skindex16 (SD-16), maximum grade of ARD, and time of initial RD occurrence. Results A total of 64 female patients with an age range of 33 to 79 years were included. The means (SD) of age were 53.88 (11.02) and 54.88 (12.48) in the control and timolol groups, respectively. Considering the RTOG/EORTC and CTCAE scores the difference between groups was insignificant (P-Value = 0.182 and P-Value = 0.182, respectively). In addition, the mean (SD) of time of initial RID occurrence in placebo and timolol groups were 4.09 (0.588) and 4.53 (0.983) weeks, respectively (P-Value = 0.035). The maximum grade of RID over time was significantly lower in the timolol group. During the study period, 75.0% of patients in placebo groups had grade 2 of ARD while in the timolol group it was 31.3% (P-Value = 0.002). QoL was not significantly different between groups (P-Value = 0.